Latest news with #NXTC
Business Insider
11 hours ago
- Health
- Business Insider
NextCure presents new preclinical data on osteogenesis imperfecta treatment
NextCure (NXTC) announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. The data were presented at the Brittle Bone Society Meeting on July 24th, 2025. These results demonstrate that NC605 could be a highly effective treatment for OI, also known as brittle bone disease. OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. There is no cure for OI. Current anti-resorptive treatments inhibit both bone loss and bone formation leading to an increase in bone density, but overall poor bone quality. In contrast, NC605 has been shown to inhibit bone loss and to produce new bone, with increased quality and density. Fracture incidence and bone architecture were assessed in male and female OI mice treated with weekly 20 mg/kg of surrogate antibody NP159 and compared to control groups treated with twice weekly 50 mg/kg anti-sclerostin or saline. NP159 increased cortical and trabecular bone mineral density, tissue mineral density, cortical thickness and decreased trabecular separation compared to saline-treated mice. 'In a mouse model of moderate-to-severe OI, NP159, a surrogate murine antibody for NC605, improved trabecular and cortical bone density and reduced fracture incidence comparable to anti-sclerostin,' said Priyanka Kothari, Ph.D., NextCure's Director, Translational Research. 'There is currently no standard of care approved by the FDA for patients with OI and NC605 has the potential to provide significant therapeutic benefit for patients.'
Reuters
16-06-2025
- Business
- Reuters
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug
June 16 (Reuters) - Drug developer NextCure (NXTC.O), opens new tab said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming ( opens new tab to develop a cancer therapy for solid tumors. NextCure said it will gain global rights to the experimental therapy, SIM0505, in all regions except Greater China, where Simcere Zaiming will retain control. Zaiming is eligible to receive payments throughout the potential development phases, including upfront payment and other milestones up to $745 million, as well as tiered royalties up to double digits on net sales outside China, NextCure added. Simcere's SIM0505 belongs to a class of drugs known as antibody-drug conjugates (ADCs), which are more targeted than conventional chemotherapy. These therapies, also known as 'guided missiles', use antibodies to deliver toxic drugs directly to cancer cells, helping to destroy the tumor while leaving healthy cells unharmed. U.S. drugmakers have been licensing drugs from China for potential new medicines at an accelerating pace, as they look to rebuild pipelines of future products while facing a patent cliff for the older drugs. The experimental cancer drug is currently being tested in an early-stage trial in China. Initial data from the trial is expected in the first half of next year. The company expects to begin studying the drug in the U.S. in the third quarter of 2025.
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
